The US FDA approved vepdegestrant (brand Veppanu) on 1 May 2026 — the first approved PROTAC (proteolysis-targeting chimera) drug, which destroys a disease-causing protein instead of merely blocking it.
It treats adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one endocrine therapy; developed by Arvinas with Pfizer.
In the Phase 3 VERITAC-2 trial (624 patients), it raised median progression-free survival in ESR1-mutant patients to 5.0 months versus 2.1 months on fulvestrant (hazard ratio 0.57).
A two-armed molecule: one end grips the target protein, the other an E3 ubiquitin ligase. The ligase tags the protein with ubiquitin and the cell's proteasome shreds it. The PROTAC is released and reused, so one molecule removes many proteins.
Simple Analogy: Not jamming a faulty machine, but calling the scrap collector to haul it away.
| Approach | Example | How it works |
|---|---|---|
| SERM | Tamoxifen | Blocks the receptor in breast tissue |
| SERD | Fulvestrant (injection); elacestrant (oral, FDA 2023) | Binds the receptor and speeds its breakdown |
| PROTAC degrader | Vepdegestrant (oral, FDA 2026) | Recruits an E3 ligase so the proteasome destroys the receptor; acts catalytically |
Aaron Ciechanover, Avram Hershko and Irwin Rose, for discovering ubiquitin-mediated protein degradation — the machinery PROTACs hijack
Proteins with no pocket to block can still be degraded, widening the range of drug targets
PROTACs in development for Parkinson's disease, spinal-bulbar muscular atrophy and other cancers
GS Paper III > Science and Technology — biotechnology, health
General Science > Biology in news
Proteolysis-targeting chimera — a molecule that links a target protein to an E3 ligase for destruction
Small protein tag that marks other proteins for disposal
Cellular complex that breaks tagged proteins into peptides
Change in the estrogen-receptor gene that often emerges during hormone therapy and causes resistance